Dr. Lyou on Sequencing Apalutamide in Prostate Cancer

In Partnership With:

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Yung Lyou, MD, PhD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses optimal sequencing with apalutamide (Erleada) in prostate cancer.

In recent years, many options have become available for the first-line treatment of men with prostate cancer, says Lyou. However, these options have made treatment sequencing more challenging, Lyou explains.

Apalutamide is currently FDA approved to treat men with metastatic castration-sensitive prostate cancer (mCSPC), as well as nonmetastatic castration-resistant prostate cancer (mCRPC), says Lyou. As such, using apalutamide as frontline treatment for patients with castration-sensitive disease leaves the greatest number of treatment options available for patients who progress to metastatic castration-resistant prostate cancer (mCRPC), says Lyou. In mCRPC, apalutamide is not FDA approved and treatment options include docetaxel, abiraterone acetate (Zytiga) plus prednisone, or enzalutamide (Xtandi), concludes Lyou.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content